Combination Immunotherapy Targeting Sarcomas
Shenzhen Geno-Immune Medical Institute
View at source ↗Clinical trial
Source: ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters. Not a U.S. Government endorsement.
Brief summary
The aim of this clinical trial is to assess the feasibility, safety and efficacy of a combination low dose chemotherapy and immunotherapy in patients who have sarcoma that is relapsed or late staged. Another goal of the study is to assess the safety and efficacy of the therapy that combines multiple CAR T cells followed by sarcoma vaccines.
Source: ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters. Not a U.S. Government endorsement.
Trial details
- status
- NOT_YET_RECRUITING
- phase
- PHASE1, PHASE2
- study type
- INTERVENTIONAL
- enrollment
- 20
- sponsor
- Shenzhen Geno-Immune Medical Institute
- conditions
- Sarcoma; Osteoid Sarcoma; Ewing Sarcoma
- interventions
- BIOLOGICAL: Multiple sarcoma-specific CAR-T cells and sarcoma vaccines
- start date
- 2027-07-01
- start date type
- ESTIMATED
- primary completion date
- 2029-05-31
- has results
- false
- data source
- ClinicalTrials.gov
- data processed
- 2026-10-29T09:00:05
- modifications
- selected fields only; whitespace normalized; brief summary truncated to 2,000 characters
Record
- Archive ID
- nct:NCT04433221
- Published
- Jun 16, 2020
- Updated
- Aug 26, 2026
- Venue
- ClinicalTrials.gov
- ClinicalTrials.gov
- NCT04433221
- Categories
- Sarcoma, Osteoid Sarcoma, Ewing Sarcoma
- License
- ClinicalTrials.gov terms (attribution, processing date, modifications noted)
- Provenance
- clinicaltrials